Relypsa Inc In a research report issued today, Wedbush analyst Liana Moussatos weighed in on drug maker Relypsa Inc (NASDAQ:RLYP), after the company released Veltassa (patiromer) …
Recently, various executives have taken part in insider trading activity for the stocks of Netflix, Inc. (NASDAQ:NFLX), Ariad Pharmaceuticals, Inc.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) reported financial results for the first quarter of 2016, including revenue from sales of Iclusig®(ponatinib).
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) and Incyte Corporation (NASDAQ:INCY) announced the entry into a definitive agreement for Incyte to acquire ARIAD’s European operations.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced the results of comprehensive preclinical studies on its investigational tyrosine kinase inhibitor (TKI), AP32788, at the American Association …
Healthcare analysts expressed their views on drug makers Celldex Therapeutics, Inc. (NASDAQ:CLDX) and Ariad Pharmaceuticals, Inc.
With earnings season around the corner, analysts from Cowen & Co. are weighing in with expectations for some of the most notable names …
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced updated clinical data on its investigational tyrosine kinase inhibitor, brigatinib, in patients with advanced malignancies, including anaplastic lymphoma kinase …
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced the initiation of a randomized, first-line Phase 3 clinical trial of brigatinib, its investigational anaplastic lymphoma kinase (ALK) inhibitor, …
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced the appointment of Manmeet S.
